InsiderTrades.com logo
Tesla Execs are Freaking Out
From Angel Publishing   |   Ad
It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.
Click here to get the details.

CALC Insider Trading

Insider Ownership Percentage: 41.55%
Insider Buying (Last 12 Months): $4,634,998.09
Insider Selling (Last 12 Months): $0.00

CalciMedica Insider Trading History Chart

This chart shows the insider buying and selling history at CalciMedica by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CalciMedica Share Price & Price History

Current Price: $3.45
Price Change: ▲ Price Increase of +0.1 (2.99%)
As of 11/20/2024 01:00 AM ET

This chart shows the closing price history over time for CALC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Download Our Tesla Ebook For Free
From DTI   |   Ad
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
To claim your copy free of charge simply follow this link.

CalciMedica Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2024A. Rachel LehenyCEOBuy20,000$3.75$75,000.00130,926View SEC Filing Icon  
11/1/2024Eric W RobertsInsiderBuy53,333$3.75$199,998.75164,706View SEC Filing Icon  
11/1/2024Fred A MiddletonDirectorBuy87,744$3.75$329,040.00814,300View SEC Filing Icon  
11/1/2024Sanderling Venture Partners ViMajor ShareholderBuy86,867$3.75$325,751.25814,300View SEC Filing Icon  
8/27/2024A. Rachel LehenyCEOBuy1,000$4.19$4,190.00110,926View SEC Filing Icon  
8/23/2024Eric W RobertsInsiderBuy5,000$3.57$17,850.0046,894View SEC Filing Icon  
8/23/2024Robert N WilsonDirectorBuy54,000$3.72$200,880.00364,196View SEC Filing Icon  
8/21/2024Eric W RobertsInsiderBuy5,000$4.04$20,200.0044,894View SEC Filing Icon  
6/27/2024Eric W RobertsInsiderBuy5,000$3.22$16,100.0010,223View SEC Filing Icon  
6/27/2024Robert N WilsonDirectorBuy8,443$3.23$27,270.89258,918View SEC Filing Icon  
4/1/2024Eric W RobertsInsiderBuy746$3.90$2,909.4036,640View SEC Filing Icon  
1/23/2024Fred A MiddletonDirectorBuy679,384$3.70$2,513,720.80946,744View SEC Filing Icon  
1/23/2024Sanderling Venture Partners ViMajor ShareholderBuy243,356$3.70$900,417.20946,744View SEC Filing Icon  
12/11/2023Robert N WilsonDirectorBuy506$3.30$1,669.80182,161View SEC Filing Icon  
11/6/2023A. Rachel LehenyCEOBuy2,440$3.12$7,612.8016,840View SEC Filing Icon  
11/6/2023Eric W RobertsInsiderBuy2,400$3.12$7,488.0035,894View SEC Filing Icon  
11/3/2023A. Rachel LehenyCEOBuy5,000$2.85$14,250.0014,400View SEC Filing Icon  
11/3/2023Eric W RobertsInsiderBuy3,200$2.80$8,960.0016,587View SEC Filing Icon  
8/25/2023Eric W RobertsInsiderBuy736$3.18$2,340.485,000View SEC Filing Icon  
8/21/2023Eric W RobertsInsiderBuy1,750$3.25$5,687.503,550View SEC Filing Icon  
6/26/2023Eric W RobertsInsiderBuy1,200$3.70$4,440.0013,387View SEC Filing Icon  
6/23/2023Eric W RobertsInsiderBuy500$3.35$1,675.0016,185View SEC Filing Icon  
See Full Table
Trump said you could learn something from this man
From Wide Moat Research   |   Ad
Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.
Here’s everything you need to know.

SEC Filings (Institutional Ownership Changes) for CalciMedica (NASDAQ:CALC)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CALC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

CalciMedica Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2024Geode Capital Management LLC66,553$0.30M0.0%+51.2%0.619%Search for SEC Filing on Google Icon
11/5/2024BML Capital Management LLC153,887$0.68M0.4%-4.1%1.432%Search for SEC Filing on Google Icon
11/1/2024Atria Investments Inc26,503$0.12M0.0%+136.5%0.247%Search for SEC Filing on Google Icon
4/23/2024BML Capital Management LLC160,424$0.67M0.4%+10.3%1.494%Search for SEC Filing on Google Icon
2/2/2024Meritage Portfolio Management46,000$0.13M0.0%+360.0%0.810%Search for SEC Filing on Google Icon
1/30/2024BML Capital Management LLC145,424$0.42M0.3%+63.8%2.560%Search for SEC Filing on Google Icon
12/7/2023Hudson Bay Capital Management LP166,857$0.43M0.0%N/A2.938%Search for SEC Filing on Google Icon
7/31/2023Meritage Portfolio Management10,000$40K0.0%N/A0.177%Search for SEC Filing on Google Icon
7/24/2023BML Capital Management LLC88,781$0.36M0.3%N/A1.568%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
CalciMedica logo
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Read More on CalciMedica

Today's Range

Now: $3.45
Low: $3.36
High: $3.45

50 Day Range

MA: $3.96
Low: $3.33
High: $4.99

52 Week Range

Now: $3.45
Low: $2.68
High: $8.38

Volume

11,816 shs

Average Volume

36,641 shs

Market Capitalization

$46.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Who are the company insiders with the largest holdings of CalciMedica?

CalciMedica's top insider investors include:
  1. Fred A Middleton (Director)
  2. Sanderling Venture Partners Vi (Major Shareholder)
  3. Robert N Wilson (Director)
  4. Eric W Roberts (Insider)
  5. A Rachel Leheny (CEO)
Learn More about top insider investors at CalciMedica.

Who are the major institutional investors of CalciMedica?

CalciMedica's top institutional investors include:
  1. BML Capital Management LLC — 1.43%
  2. Geode Capital Management LLC — 0.62%
  3. Atria Investments Inc — 0.25%
Learn More about top institutional investors of CalciMedica stock.

Which institutional investors are selling CalciMedica stock?

Within the last quarter, CALC stock was sold by these institutional investors:
  1. BML Capital Management LLC

Which institutional investors are buying CalciMedica stock?

In the last quarter, CALC stock was purchased by institutional investors including:
  1. Geode Capital Management LLC
  2. Atria Investments Inc
Within the previous year, these company insiders have bought CalciMedica stock:
  1. Fred A Middleton (Director)
  2. Sanderling Venture Partners Vi (Major Shareholder)
  3. Robert N Wilson (Director)
  4. Eric W Roberts (Insider)
  5. A Rachel Leheny (CEO)
Learn More investors buying CalciMedica stock.
Tesla Execs are Freaking Out
From Angel Publishing   |   Ad
It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.
Click here to get the details.